1	Joint modeling HIV and HPV using a new hybrid agent-based network and compartmental
2	simulation technique
3	Xinmeng Zhao <sup>1</sup> , *Chaitra Gopalappa <sup>1</sup>
4	
5	<sup>1</sup> Department of Mechanical and Industrial Engineering, University of Massachusetts Amherst,
6	MA, USA
7	
8	*Corresponding author:
9	e-mail: <u>chaitrag@umass.edu</u>
10	
11	Acknowledgments
12	This work was funded by the National Science Foundation under grant #1915481. The funding
13	agreement ensured the authors' independence in designing the study, interpreting the data,
14	writing, and publishing the report.
15	
16	Authors' contributions
17	Xinmeng Zhao: methodology, data curation, output analysis and review, validation and
18	visualization, manuscript preparation and review. Chaitra Gopalappa: conceptualization, output
19	analysis and review, manuscript preparation and review. The authors read and approved the final
20	manuscript.
21	
22	

### 23 Abstract

24 **Introduction:** Persons living with HIV have a disproportionately higher burden of HPV-related 25 cancers. Causal factors include both behavioral and biological. While pharmaceutical and care 26 support interventions help address biological risk of coinfection, as social conditions are 27 common drivers of behaviors, structural interventions are key part of behavioral interventions. Joint modeling sexually transmitted diseases (STD) can help evaluate optimal intervention 28 29 combinations for overall disease prevention. While compartmental modeling is sufficient for 30 faster spreading HPV, network modeling is suitable for slower spreading HIV. However, using 31 network modeling for jointly modeling HIV and HPV can generate computational complexities 32 given their vastly varying disease epidemiology and disease burden across sub-population 33 groups.

34 Methods: We applied a recently developed mixed agent-based compartmental (MAC) 35 simulation technique, which simulates persons with at least one slower spreading disease and 36 their immediate contacts as agents in a network, and all other persons including those with faster 37 spreading diseases in a compartmental model, with an evolving contact network algorithm 38 maintaining the dynamics between the two models. We simulated HIV and HPV in the U.S. 39 among heterosexual female, heterosexual male, and men who have sex with men (men only and 40 men and women) (MSM), sub-populations that mix but have varying HIV burden, and cervical 41 cancer among women. We conducted numerical analyses to evaluate the contribution of 42 behavioral and biological factors to risk of cervical cancer among women with HIV.

43 **Results:** The model outputs for HIV, HPV, and cervical cancer compared well with surveillance 44 estimates. Behavioral factors significantly contributed to risk of HIV-HPV co-infection, and 45 biological factors further exacerbated cancer burden among persons with HIV, with the fraction 46 attributed to each factor sensitive to disease burden.

47 Conclusions: This work serves as proof-of-concept of the MAC simulation technique for joint
48 modeling related diseases with varying epidemiology in sub-populations with varying disease
49 burden. Future work can expand the model to simulate sexual and care behaviors as functions of

- 50 social conditions, and further, jointly evaluate behavioral, structural, and pharmaceutical
- 51 interventions for overall STD prevention.
- 52 Keywords: Agent-based simulation; hybrid-simulation model; multi-disease model; infectious
- 53 disease model.

### 55 Introduction

56 Human papillomavirus virus (HPV) is one of the most common sexually transmitted diseases 57 (STDs) in the United States, about 80% of sexually active persons are estimated to have acquired 58 HPV at least once during a lifetime [1,2]. Although most HPV infections resolve on their own 59 within 2 years, persistent infection with certain types of HPV (high-risk or oncogenic HPV) are a 60 causal factor for most cases of cervical cancer [3-5] and anal cancers [6-8], and a likely cause of 61 substantial proportions of other genital neoplasms and oral squamous cell carcinomas [4,9]. On 62 average, each year in the United States, about 12,000 women are estimated to be diagnosed with 63 cervical cancer, and an additional 11,000 women and 16,000 men are annually diagnosed with 64 other HPV-associated cancers [10]. Persons with impaired cell-mediated immunity, such as 65 persons with human immunodeficiency virus (HIV) infection, particularly suffer from increased 66 risk of HPV infection and subsequent genital tract neoplasias and cancers [11–13]. For example, 67 the risk of HPV infection and cervical cancer incidence among women with HIV compared to 68 women without HIV were estimated to be about ~2-6 times [14–16] and ~2-7 times higher, 69 respectively [17–19].

70 Causal factors for higher risk of HPV infection among persons with HIV could be attributed to 71 behavioral factors, i.e., individual sexual behaviors, partnership networks, and care behaviors, 72 and biological factors, i.e., a compromised immune system from HIV can biologically increase 73 the risk of other diseases [20,21]. Studies in the literature have investigated the attribution to 74 biological factors by using observational data and statistically accounting for the confounding 75 factors of sexual behavior. These include estimating associations between HIV exposure and 76 HPV acquisition [22–25], rate of HPV clearance [26–28], and risk of HIV on disease progression and cervical cancer pathology [29–35]. The primary focus of these studies is on biological 77 78 factors, and most studies are based on statistical methods such as multivariate regression 79 analyses. However, they do not consider the dynamics of behavioral factors, such as changes in 80 individual behaviors, partnership networks, and system-level changes in care.

81 Quantitative estimations of the risk of HIV-HPV coinfection, attributable to each type of factor,

82 behavioral and biological, could help inform the type of intervention needs. Specifically, social

83 conditions, such as poverty, unemployment, stigma, and discrimination, are key drivers of

84 behaviors that increase risk of STIs, e.g., higher number of partners, higher condomless sex, 85 lower care uptake among persons experiencing homelessness than among those with stable 86 housing [36–39]. Consequently, though the prevalence of HIV in the U.S. is low, it is 87 concentrated among the most vulnerable populations. Among persons living with diagnosed HIV 88 infection, an estimated 44% had a disability (including physical, mental, and emotional 89 disabilities), 41% were unemployed, 43% had household incomes at or below the federal poverty 90 threshold, and 10% were experiencing homelessness [40,41]. Thus, structural interventions, such 91 as health care coverage, subsidized housing and food programs, and access to mental healthcare 92 are key part of behavioral interventions for prevention of STIs [42–45]. On the other hand, 93 biological risk of coinfection would additionally require pharmaceutical and care support

94 programs for disease management.

95 A dynamic model of sexual transmission networks that jointly simulates HIV and HPV will

96 serve as a suitable decision-analytic tool for analyses of structural and disease-specific

97 interventions. Several models in the literature have jointly simulated HIV and HPV for economic

98 analyses of interventions such as antiretroviral therapy treatment and pre-exposure prophylaxis

99 for HIV and HPV vaccinations and cervical cancer screening for women [46–50]. Most models

100 are deterministic compartmental models [46,47,50], and the models that are individual based do

101 not include a transmission model [48] or do not explicitly simulate partnership networks [49],

102 which limit the capacity to fully account for the behavioral interactions between HIV and HPV

103 infections.

104

We built a joint HIV-HPV simulation model using a mixed agent-based network and compartmental (MAC) simulation framework and conducted numerical analyses to evaluate the risk of coinfection attributable to behavioral and biological factors. These numerical findings will help inform intervention needs and, in future work, help conduct model evaluations of both structural interventions and disease-specific interventions. While observational studies can help estimate the costs, the behavioral interactions in the model can help evaluate the impact of structural interventions on overall STI prevention.

112

### 113 Methods

114 MAC is a recently developed simulation framework for joint modeling diseases of varying 115 epidemiology [51]. While compartmental modeling is sufficient for higher prevalence diseases 116 such as HPV, Chlamydia, and Gonorrhea, agent-based network modeling is preferred for slower 117 spreading diseases such as HIV and Hepatitis C, as the network structures have a larger influence 118 on disease spread [52]. However, agent-based modeling alone will be computationally 119 challenging for national joint disease modeling. For example, in the U.S., HIV prevalence is 120 about 0.4% and 25% of HIV infected persons are women [53] and cervical cancer prevalence 121 among HIV infected women is 0.3% [54]. Thus, simulating 100,000 persons representative of 122 the U.S. population will generate 100 women with HIV, and no cases of cervical cancer. 123 Increasing the number of samples will exponentially increase the challenges with computational 124 tractability. Similar challenges are faced when modeling sub-populations with disproportionately 125 varying disease burden. For example, in the U.S., about 64% of HIV cases are among men who 126 have sex with men [53], who constitute about 2% of the U.S. population [55]. Most HIV network 127 models in the literature simulate sub-populations separately, which overlooks the mixing 128 associated between sub-groups, e.g., about half of new HIV cases among women were linked to 129 transmissions from MSM [56,57]. The MAC framework overcomes the computational 130 challenges by simulating persons with at least one lower prevalence disease and their immediate 131 contacts in an agent-based network model, and all other persons including those with only higher 132 prevalence diseases in a compartmental model, using an agent-based evolving network algorithm 133 (ABENM) to maintain the network dynamics between persons in the two models [58,59]. The 134 MAC simulation framework has been described elsewhere [51], and ABENM for simulating 135 sexual transmission networks in the U.S. has been applied to the 'Progression and Transmission 136 of HIV' (PATH 4.0) model in the U.S. [59], and extensively validated against multiple epidemic 137 and network metrics from the U.S. National HIV Surveillance Systems.

138 In this work, we used MAC to build a two-disease model, calibrating to lower prevalence HIV

and higher prevalence HPV, and validating against data in the U.S., to serve as proof-of-concept

140 of the MAC framework. We provide a brief overview of MAC below and the HIV-HPV model

141 development and calibration.

medRxiv preprint doi: https://doi.org/10.1101/2022.12.25.22283941; this version posted December 27, 2022. The copyright holder for this preprint doi: https://doi.org/10.1101/2022.12220391, this estimated medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

#### 143 **Overview of MAC**

144 We present an overview of the MAC simulation framework for HIV-HPV modeling in Fig 1. All

- 145 persons in the population are ether in the network or in the compartmental model. Persons
- 146 infected with the lower prevalence HIV (they may also be infected with HPV), and their
- 147 immediate contacts are tracked in the network and all other persons, including those with only
- 148 higher prevalence HPV and those uninfected with either disease are tracked in a compartmental
- 149 model. We newly calibrated an HPV model for the U.S. population and adopted the HIV model
- 150 from the previously validated PATH 4.0 model [59]. Details of MAC are presented in [51], we
- 151 present below an overview of the computational structure of MAC, an overview of the
- 152 calibration of HIV and HPV, and numerical analyses. We simulated HIV and HPV among three
- 153 transmission risk groups: heterosexual women (HETF), heterosexual men (HETM), and men
- 154 who have sex with men (MSM) (men only and women). We present in the Appendix more
- 155 details of the computational structure of MAC in Appendix S1, including HIV and HPV modules
- 156 in Appendix S1.3, and details of the HPV model calibration in Appendix S2.
- 157



- 160 161
- 162 Computational structure of MAC

163 The model tracks HIV-infected persons and immediate contacts using a dynamic graph

- 164  $G_t(\mathcal{N}, \mathcal{E})$ , with the number of nodes in the graph  $Q_t = |\mathcal{N}(G_t)|$  and the number of edges  $|\mathcal{E}(G_t)|$
- 165 dynamically changing over time t as persons become newly infected with HIV and their
- 166 immediate contacts are added to the network. Each person in the network has attributes such as
- age, transmission-group, degree (number of lifetime partnerships), geographic jurisdiction, HIV-
- 168 related disease and care continuum stages, and HPV related disease and care stages.
- 169

170 The model tracks all other persons in a compartment model, using an array  $S_t$  of size

171  $A \times R \times D \times G \times H$ , where, A is the number of age-groups, R is the number of transmission-

172 groups, *D* is the number of degree-bins (degree is the number of lifetime partners per person,

- 173 degrees are grouped into bins analogous to age grouped into age-groups), *G* is the number of
- 174 geographic jurisdictions (in our numerical analyses we assumed G = 1, corresponding to a

175 national jurisdiction), and *H* is the number of health states related to HPV including disease-free

176 state. Each element of the array  $(S_t[\bar{a}, r, \bar{d}, g, h])$  is the number of people in that specific

177 category. We use a dash for age-group and degree-bin notations to indicate that they are grouped

178 intervals in the compartmental model, unlike in the network where each node has a discrete

179 value. A summary list of notations is presented in Appendix Table S1.

180

181 Thus,  $Q_t + \sum_{i \in [\bar{a}, r, \bar{d}, g, h]} S_{t,i}$ , would be the total number of people in the population at time *t*. As 182 all HIV infected persons and exposed partners are in the network, HIV transmissions and disease 183 stage progressions are modeled at the individual level (as typically done in agent-based 184 modeling). HPV transmissions and progression are modeled using differential equations (as 185 typically done in compartmental modeling technique) but with the consideration that people in 186 both the network  $G_t(\mathcal{N}, \mathcal{E})$  and compartmental array  $S_t$  can be infected with HPV.

187

188 The model adopts the concepts from a previously developed ABENM simulation technique

- [58,59] to maintain the dynamics between the network  $G_t(\mathcal{N}, \mathcal{E})$  and compartmental array  $S_t$ ,
- 190 including transitioning people from  $S_t$  to  $G_t(\mathcal{N}, \mathcal{E})$  when they become newly infected with HIV.
- 191 As HIV infection is chronic once persons enter the network  $G_t(\mathcal{N}, \mathcal{E})$  they do not transition back
- 192 to  $S_t$ . More details of the MAC computational structure are provided in Appendix S1.1 and S1.2.
- 193

The overall epidemiological, demographical, and network dynamics are maintained through simulation of four main modules that are run at every time-step (monthly) of the simulation: compartmental module for HPV transmissions and progression, network transmission module for HIV transmissions, ECNA network generation module for maintaining partnership dynamics and network dynamics between the compartmental model and the network, and network disease progression module for HIV progression. We discuss each module in Appendix S1.3 and provide an overview of each below.

201

202 The compartmental module updates the demographic features (births, aging, and deaths) among 203 persons tracked through the array  $S_t$ . It also models transmission and progression features of 204 high-prevalence diseases (HPV here) among persons tracked through the array  $S_t$  and in the 205 network  $G_t(\mathcal{N}, \mathcal{E})$ . Specifically, as in typical compartment modeling, it uses difference equations 206 to calculate the rate of transitioning between compartments that represent HPV disease stages. It 207 also uses those rates to determine the number of people in the network to transition between 208 states corresponding to those compartments. A key feature here is approximating network 209 structures within the compartmental model by using degree-bins as part of the model framework 210 (a dimension in array  $S_t$ ) and using a degree-mixing matrix to simulate partnerships that can 211 occur with people in different degree-bins. Degree, in addition to age and transmission-group, 212 between partners are correlated [60] and thus this feature helps better capture the network 213 dynamics even in the compartmental model. While the distributions for partnership mixing by 214 age-group, transmission-group, and degree-bin are applied at the individual level in the network 215 they are applied at the aggregated level in the compartmental model. The general MAC 216 computational structure of the compartmental module is presented in Appendix S1.3.1 and its 217 application specific to HPV is presented in Appendix S2.

218

The network transmission module uses an individual-level Bernoulli transmission equation to determine if nodes in the network  $G_t(\mathcal{N}, \mathcal{E})$  exposed to a lower prevalence disease (HIV here) become infected. Transmissions are determined at the individual level using the network structure and individual-level sexual behaviors and transmission risk factors. We present an overview of the HIV Bernoulli transmission equation in Appendix 1.3.2. Note that, as persons in the compartmental model are not partners of any person infected with the lower prevalence

diseases (HIV here), their chance of infection is zero. Further note that persons can move from
 the compartmental model to the network (Fig 1) upon becoming partners of an HIV-infected

227 person, modeled using the ECNA module (discussed below), which would then expose them to

- the infection. We adopted the HIV transmission module from PATH 4.0 [59].
- 229

230 The ECNA module controls the overall network dynamics of partnerships between persons in the 231 compartmental model and the network. Specifically, for every node newly infected with HIV in 232 the network, it determines the number of new partnerships to generate and the features of each of 233 those new partners, including their number of lifetime partners, their transmission-group, and 234 their current age-group. The module then randomly selects susceptible persons who meet these 235 criteria and moves them from the compartmental model to the network. As all life-time 236 partnerships of an HIV-infected person are in the network, contacts need to be activated and 237 deactivated as per when the partnership initiates and terminates. The ECNA module determines 238 these partnership details, such as the age of both partners and simulation times at partnership 239 initiation and termination. It does so by using multiple sub-algorithms developed using concepts 240 from machine learning, stochastic processes, and optimization, which are presented in [58,59] 241 and are summarized in Appendix S1.3.3.

242

Finally, the network disease progression module updates the individual-level demographic and
disease dynamics for every person infected with HIV (and other lower prevalence diseases in its
general application) in the network. We adopted the HIV progression module from [56,59].
.

247

# 248 Model calibration and validation

HIV: We adopted the validated HIV model from PATH 4.0 as lower prevalence Disease 1 [59].
PATH 4.0 was validated to match well against data from the National HIV Surveillance System
(NHSS) for both epidemic features and network features. Details of the ABENM, PATH 4.0, and
its validation are presented in [59]; we give a brief description below. PATH 4.0 simulates
sexual transmission of HIV in the U.S. in three transmission risk groups: HETF, HETM and
MSM. The model is first initialized to be representative of people living with HIV (PWH) in the
U.S. in 2006, using data from several studies. These include demographical, sexual behavioral,

clinical, and HIV care and treatment behavioral studies that originated from multiple large

257 national surveillance and survey systems in the U.S., along with other small studies. The

surveillance and survey systems include the NHSS, the Medical Monitoring Project (MMP), the

259 HIV Outpatient Study (HOPS), the National HIV Behavioral Surveillance (NHBS), the National

260 Survey for Family Growth (NSFG), and the National Survey for Sexual Health and Behavior

261 (NSSHB) [61–66]. After initialization to 2006, the model then simulates HIV from 2006 to 2017

in monthly-time steps, using data for annual changes in care continuum from NHSS [59].

263 HPV: We constructed a new HPV and cervical cancer model as higher prevalence Disease 2.

264 Detailed description of model development, data assumptions, calibration, and validation are

265 presented in Appendix 2, and summarized below. The compartmental model array  $S_t$  was of size

 $7 \times 3 \times 9 \times 1 \times 41$ , corresponding to size of age-group, transmission risk group, degree-bin,

267 geographical jurisdiction, and HPV health state. Here we simulated an overall national

268 population, thus, there was only 1 jurisdiction.

269 Note that, as in the HIV model, there were three transmission-groups, HETF, HETM, and MSM.

270 For HETF, we simulated HPV and cervical cancer. For HETM, we simulated only HPV as the

risk of sequelae among HETM is low. For MSM, anal HPV can lead to cancers such as anal

272 cancer, which has a similar epidemiology as cervical cancer [67]. We did not specifically model

anal cancer. However, as HIV prevalence and sexual networks among MSM are significantly

274 different than among heterosexuals, to understand the mathematical sensitivity of these network

275 dynamics on metrics of interest (see numerical analyses below), we used the disease progression

276 data for HPV and cervical cancer to model HPV and anal cancer among MSM. Thus, we

277 validated this model for only HPV and cervical cancer among women.

Sexual behavioral data, such as the number of sex acts, condom use, and partnership mixing across age-groups and transmission groups, were kept consistent between the compartmental and network models (as they collectively represent the U.S population). That is, data specific to agegroup, transmission risk group, and degree-bin from PATH 4.0 were also used in the estimation of HPV infection rates, i.e., the rate of transitioning from susceptible to first stage of infection. Data for the state-transitions related to natural HPV progression and regression were gathered from literature studies [47,68–70]. We calibrated the per-act probability of transmission specific

to HPV-genotype by fitting the natural history model to common calibration targets e.g., highrisk HPV genotype frequency among cervical intraepithelial neoplasia (CIN) 1, 2, 3, and normal
cytology and age-and genotype-specific high-risk HPV prevalence among normal cytology [71]
as typically done in other models in the literature [72]. Results show a good fit to most metrics
(Fig 2). To assess the validity of the model, we compared pre-screening cervical cancer
incidence and mortality from our model with the data obtained from the Connecticut Tumor
Registry (Fig 3a) [73].



292

293 Fig 2. HPV and cervical cancer natural history model calibration results.

a) Age-and genotype-specific high-risk HPV prevalence among normal cytology; b) Age-

specific HPV prevalence among normal cytology; c) High-risk HPV genotype frequency among

cervical intraepithelial neoplasia (CIN) 1, 2 and 3. (Data source: [71]).

16/18 represent HPV-16/18 pooled, HI5 represents HPV-31/33/45/52/58 pooled, while OHR represents other high-risk genotypes except HPV-16/18/31/33/45/52/58.

300

We used the calibrated model to simulate and validate HPV in the U.S under cervical cancer screening, using data corresponding to 2006. These data include screening rates, cytology screening sensitivity, proportions receiving follow-up colposcopy/biopsy and proportion receiving precancer treatment for those in pre-cancer stages, and additionally cancer-screening sensitivity for those in cancer stages [74,75]. Cervical cancer incidence and mortality in 2006 with screening [76] compare well with surveillance estimates (Fig 3b). More details on calibration and validation are provided in Appendix 2.5.



309 Fig 3. HPV and cervical cancer natural history model validation results.

a) Age-specific cervical cancer incidence and mortality per 100,000 women (without screening);

- b) Age-specific cervical cancer incidence and mortality per 100,000 women (with screening).
- 312 (Data source: a) [73]; b) SEER 2006 [76]).
- 313

308

# 314 Numerical analyses

- 315 We focused the numerical analyses on estimating the differences in HPV disease burden among
- 316 people with HIV compared to people without HIV. In this regard, we define the following
- 317 relative risk metrics, relative prevalence of HPV  $(RP_{HPV})$  and relative incidence of cancer
- 318  $(RI_{cancer})$ .

319 
$$RP_{HPV} = \frac{HPV \text{ prevalence among people with HIV in 2017}}{HPV \text{ prevalence among people without HIV in 2017}}$$

# 320 RI<sub>cancer</sub>

321

# $= \frac{Cumulative \ cancer \ incidence \ between \ 2008 \ and \ 2017 \ among \ people \ with \ HIV}{Cumulative \ cancer \ incidence \ between \ 2008 \ and \ 2017 \ among \ people \ without \ HIV}$

322

323 Prevalence is the proportion of people living with the disease, calculated at the end of 2017, and

includes both diagnosed and undiagnosed cases. Cancer incidence is the number of newly

325 diagnosed cases in a year. We used prevalence for  $RP_{HPV}$  but cumulative incidence for  $RI_{cancer}$ 

because persons in an HPV infection state can transition back to a susceptible state, while

327 persons transitioning to a cancer state remain in that state until mortality.

328

# 329 Scenarios modeled

330 To determine the attribution of biological and behavioral factors to the higher HPV burden

among women with HIV, we estimated  $RP_{HPV}$  and  $RI_{cancer}$  under four assumptions of

biological risk (discussed below). Further, to evaluate the sensitivity of  $RP_{HPV}$  and  $RI_{cancer}$  to

changes in HPV burden over time, caused by changes in interventions, we evaluated the metrics

under three HPV intervention assumptions (discussed below). Thus, we evaluated a combination

of twelve scenarios. We discuss each of the four biological risk assumptions and three HPV

intervention assumptions below. As HIV care has significantly increased over the past decade, to
 test the sensitivity of the relative risk metric to HIV burden, for each scenario, we evaluated

338  $RP_{HPV}$  at two-time points years 2010 and 2017.

339

340 Biological risk assumptions:

*No biological risk*: Assumes incidence and progression rates for HPV and related cancers
 would be the same for persons with HIV and without HIV (note: incidence and

343 progression rates do change by other factors such as age-group, sexual behavior, etc.).

344 The values for these were taken from data in the literature and are discussed in Appendix

345 S2.4.1. We assume these to be the basecase rates.

*Increased risk of disease progression*: Assumes higher rates of HPV progression and
 lower rates of HPV regression for persons with HIV infection compared to persons

- 348 without (through use of a factor multiplied to basecase rates). Further, the value of the
- 349 multiplier varied by HIV-disease stage. Data for these multipliers were based on studies

350		in the literature (Appendix Table S2) [47,77,78]. Though these data were specific to
351		cervical cancer, due to lack of data we assumed same multipliers when modeling anal
352		cancer among MSM, as studies suggest higher biological risk for anal cancer [11–13].
353	-	Increased risk of HPV acquisition: Assumes a higher rate of HPV acquisition for persons
354		with HIV compared to persons without HIV by using a multiplier to the basecase
355		infection rates. Data for these multipliers were based on studies in the literature
356		(Appendix Table S2) [47]. Though these data were specific to cervical cancer, due to
357		lack of data we assumed same multipliers when modeling anal cancer among MSM, as
358		studies also suggest higher biological risk for anal cancer [11–13].
359	-	All increased risk: Combines the above two scenarios by assuming higher rates of HPV
360		acquisition, higher rates of HPV progression, and lower rates of HPV regression for
361		persons with HIV infection compared to persons without.
362	Interv	ention assumptions:
363	•	Pre-screening: Assumes symptom-based diagnosis for HPV and cervical cancer.
364	•	Screening-only: Assumes screening rates as per year 2006 in the U.S. and keeps it
365		constant over the period 2006 to 2017.
366	•	Status-quo intervention: Assumes screening rates as per year 2006 in the U.S. and keeps
367		it constant over the period 2006 to 2017. Additionally, it models HPV vaccinations. It
368		assumes vaccinations initiated in 2007 for females and 2010 for males aged 13-17 years,
369		assumes a quadrivalent vaccine type for the period before 2015 and nonavalent vaccine
370		for 2015 and after, and models' vaccination rates to vary per year as per data in the U.S.
371		[79–81]. This scenario is the closest representation for screening practice and HPV
372		vaccination coverage in the U.S. for recent years.
373		
374	Metri	cs gathered

We simulated each of the 12 scenarios 10 times (simulating over the period from 2006 to 2017).

We present the mean and range of  $RP_{HPV}$  and  $RI_{cancer}$  across the 10 runs. Values of greater than

- 1 indicate higher burden among persons with HIV compared to persons without. We also
- estimated the fraction of increased risk attributed to biological factors as  $[(RP_{HPV} \text{ in 'all }$
- 379 increased risk' minus  $RP_{HPV}$  in 'no biological risk') divided by  $(RP_{HPV}$  in 'no biological risk'
- minus 1)]. To better interpret observed values of  $RP_{HPV}$  and  $RI_{cancer}$ , we also extracted results

381 for the following metrics related to network and epidemic dynamics. Average degree (number of

382 lifetime partners) among HIV+  $(d_{HIV+})$ , average degree among HPV+  $(d_{HPV+})$ , average degree

among overall population (Overall) ( $d_{overall}$ ), HPV prevalence among HIV+, HPV prevalence

among HIV-, cancer incidence among HIV+, and cancer incidence among HIV-. We extracted

these metrics specific to each transmission risk group, HETF, HETM, and MSM.

386

387

### 388 Results

389 As expected, in all scenarios, HIV prevalence was highest among MSM (~8%), moderate among

HETF (~0.12%), and lowest among HETM (~0.06%), which matches with estimates from the

391 U.S. National HIV Surveillance System [82]. Considering the lower prevalence of HIV among

HETF, the overall HPV prevalence and cervical cancer incidence among women did not

393 significantly vary across the biological risk assumptions (though values varied among HIV+

women as discussed later). Overall rates of HPV prevalence were 19%, 25%, and 29% among

395 HETF, HETM, and MSM, respectively. Annual rates of cervical cancer incidence (and

396 mortality), among HETF, in pre-screening, screening-only, and status-quo scenarios were 23

(10), 7 (3), and 7 (3) per 100,000 persons, respectively. There were no differences between

398 screening-only and status-quo given the low vaccination uptakes and short timeline from vaccine

introduction. These results match with surveillance data, which report an incidence of 7.6 per

400 100,000 persons and mortality rate of 2.4 per 100,000 persons in 2006, the year prior to

401 introduction of vaccines, and an incidence of 6.7 per 100,000 persons and mortality rate of 2.2

402 per 100,000 persons by the end of 2017 [76].

403

404 In the 'status-quo, no biological risk' scenario,  $RP_{HPV}$  was significantly greater than 1 in all three

405 transmission-groups, however, it was highest among HETF (1.41(1.36-1.44)) (Table 1c)

406 followed by MSM (1.36(1.34-1.38)) (Table 3c), and closer to 1 for HETM (1.13(1.01-1.16))

407 (Table 2c). To recollect, overall HPV prevalence was highest among MSM and HETM, and

408 overall HIV prevalence was high among MSM, moderate among HETF, and low among HETM.

409 Thus, there was no consistent pattern when comparing differences in  $RP_{HPV}$  across transmission

410 risk-group with HIV prevalence or HPV prevalence alone.

### 412 Table 1a: Numerical analyses of HIV and HPV disease burden and relevant network

# 413 metrics under "prescreening" assumption (HETF)

	Prescreening			
	No biological risk	All increased risk	Increased risk of progression	Increased risk of HPV acquisition
Average degree for HIV+	23.08(21.24-24.13)	23.29(22-24.42)	23.25(22.05-24.41)	23.25(21.6-24.61)
Average degree for overall population	13.39(13.38-13.39)	13.39(13.39-13.39)	13.39(13.39-13.39)	13.39(13.38-13.39)
Average degree for HPV+	19.13(19.12-19.13)	19.13(19.12-19.14)	19.13(19.12-19.14)	19.13(19.12-19.14)
Average degree or HIV+ and HPV+	29.03(27.19-32.52)	29.57(26.27-31.99)	30.03(27.31-32.3)	29.13(26.28-31.13)
HPV prevalence among total population (2010)	0.21(0.21-0.21)	0.21(0.21-0.21)	0.21(0.21-0.21)	0.21(0.21-0.21)
HPV prevalence among total population (2017)	0.2(0.2-0.2)	0.2(0.2-0.2)	0.2(0.2-0.2)	0.2(0.2-0.2)
Relative risk (HPV prevalence, 2010)	1.29(1.26-1.33)	1.4(1.32-1.48)	1.32(1.27-1.36)	1.36(1.29-1.39)
Relative risk (HPV prevalence, 2017)	1.35(1.27-1.45)*^	1.58(1.51-1.64) *+^	1.44(1.35-1.55) *+^	1.48(1.43-1.51) *+^
Cumulative new cancer incidence among HIV+ over year 2008-2017 (per 100, 000 persons)	359.07(138.64- 567.37)	1374.64(979.54- 1806.82)	1420.04(877.43- 1852.22)	475.71(257.81- 766.67)
Cumulative new cancer incidence among HIV- over year 2008-2017 (per 100, 000 persons)	287.63(287.59- 287.67)	287.65(287.59- 287.69)	287.64(287.59- 287.68)	287.64(287.59- 287.67)
Relative risk (cumulative cancer incidence over year 2008-2017)	1.25(0.48-1.97)	4.78(3.41-6.28) *+	4.94(3.05-6.44) *+	1.65(0.9-2.67)

414 \* indicates significant compared to relative risk = 1

415 + indicates significant compared to "no biological risk" within same intervention assumption

416 ^ indicates significant compared to 2010 estimates where HIV burden was lower

417 *†* indicates significant compared to "prescreening"

418 The criterion for significance is p < 0.05.

419

# 420 Table 1b: Numerical analyses of HIV and HPV disease burden and relevant network

# 421 metrics under "screening only" assumption (HETF)

Screening only					
No biological risk	All increased risk	Increased risk of progression	Increased risk of HPV acquisition		

Average degree for HIV+	23.02(21.92-24.16)	23.28(22.39-24.32)	23.06(21.42-23.98)	23.25(21.86-25.17)
Average degree for overall population	13.39(13.39-13.39)	13.39(13.39-13.39)	13.39(13.39-13.39)	13.39(13.39-13.39)
Average degree for HPV+	19.16(19.16-19.17)	19.17(19.16-19.17)	19.16(19.16-19.17)	19.16(19.16-19.17)
Average degree or HIV+ and HPV+	29.49(27.13-31.29)	29.92(26.58-32.06)	29.06(26.78-31.14)	29.06(27.39-31.02)
HPV prevalence among total population (2010)	0.2(0.2-0.2)	0.2(0.2-0.2)	0.2(0.2-0.2)	0.2(0.2-0.2)
HPV prevalence among total population (2017)	0.2(0.2-0.2)	0.2(0.2-0.2)	0.2(0.2-0.2)	0.2(0.2-0.2)
Relative risk (HPV prevalence, 2010)	1.28(1.22-1.32)	1.42(1.34-1.49)	1.32(1.22-1.41)	1.36(1.31-1.39)
Relative risk (HPV prevalence, 2017)	1.38(1.31-1.43) *^	1.62(1.55-1.69) * <sub>+</sub> ^†	1.45(1.36-1.53) *+^	1.48(1.41-1.58) *+^
Cumulative new cancer incidence among HIV+ over year 2008-2017 (per 100, 000 persons)	117.21(48.83- 250.26)	541.78(349.69- 769.7)	423.25(154.6-630.9)	131.9(46.51-315.89)
Cumulative new cancer incidence among HIV- over year 2008-2017 (per 100, 000 persons)	81.95(81.92-81.97)	81.94(81.93-81.96)	81.95(81.93-81.96)	81.95(81.93-81.96)
Relative risk (cumulative cancer incidence over year 2008-2017)	1.43(0.6-3.05)	6.61(4.27-9.39) *+†	5.17(1.89-7.7) *+	1.61(0.57-3.86)

422 423 \* indicates significant compared to relative risk = 1

+ indicates significant compared to "no biological risk" within same intervention assumption

424 ^ indicates significant compared to 2010 estimates where HIV burden was lower

425 † indicates significant compared to "prescreening"

426 The criterion for significance is p < 0.05.

427

#### Table 1c: Numerical analyses of HIV and HPV disease burden and relevant network 428

#### 429 metrics under "status quo" assumption (HETF)

	Status quo			
	No biological risk	All increased risk	Increased risk of progression	Increased risk of HPV acquisition
Average degree for HIV+	23.45(22.75-23.59)	23.56(22.89-23.85)	23.14(22.6-24.71)	23.2(22.17-24.14)
Average degree for overall population	13.39(13.39-13.39)	13.39(13.39-13.39)	13.39(13.39-13.39)	13.39(13.39-13.39)
Average degree for HPV+	19.22(19.21-19.23)	19.22(19.22-19.23)	19.22(19.21-19.23)	19.22(19.21-19.22)
Average degree or HIV+ and HPV+	28.9(27.72-32.4)	29.1(28.2-31.15)	29.48(27.36-31.29)	28.63(26.02-30.69)
HPV prevalence among total population (2010)	0.2(0.2-0.2)	0.2(0.2-0.2)	0.2(0.2-0.2)	0.2(0.2-0.2)
HPV prevalence among total population (2017)	0.19(0.19-0.19)	0.19(0.19-0.19)	0.19(0.19-0.19)	0.19(0.19-0.19)

Status ano

Relative risk (HPV prevalence, 2010)	1.34(1.29-1.38)	1.44(1.4-1.5)	1.33(1.22-1.45)	1.36(1.33-1.42)
Relative risk (HPV prevalence, 2017)	1.41(1.36-1.44)*^	1.67(1.64-1.71) <sup>*+^†</sup>	1.48(1.39-1.58)*+^	1.5(1.43-1.55)*+^
Cumulative new cancer incidence among HIV+ over year 2008-2017 (per 100, 000 persons)	119.97(102.02-263)	450.62(322.09- 554.08)	534.86(254.8- 942.14)	126.94(0-415.54)
Cumulative new cancer incidence among HIV- over year 2008-2017 (per 100, 000 persons)	81.91(81.91-81.92)	81.9(81.89-81.91)	81.91(81.89-81.92)	81.91(81.89-81.93)
Relative risk (cumulative cancer incidence over year 2008-2017)	1.46(1.25-3.21)*	5.5(3.93-6.77)*+†	6.53(3.11-11.5)*+	1.55(0-5.07)

430 \* indicates significant compared to relative risk = 1

431 + indicates significant compared to "no biological risk" within same intervention assumption

432 ^ indicates significant compared to 2010 estimates where HIV burden was lower

433 † indicates significant compared to "prescreening"

- 434 The criterion for significance is p < 0.05.
- 435

436

# 437 Table 2a: Numerical analyses of HIV and HPV disease burden and relevant network

# 438 metrics under "prescreening" assumption (HETM)

	Prescreening			
	No biological risk	All increased risk	Increased risk of progression	Increased risk of HPV acquisition
Average degree for HIV+	13.58(12.47-14.66)	13.37(12.05-15.37)	13.33(11.66-14.92)	13.14(11.69-13.71)
Average degree for overall population	17.25(17.25-17.25)	17.25(17.25-17.25)	17.25(17.25-17.25)	17.25(17.25-17.25)
Average degree for HPV+	25.4(25.4-25.4)	25.4(25.39-25.4)	25.4(25.39-25.4)	25.4(25.39-25.4)
Average degree or HIV+ and HPV+	17.89(15.3-21.43)	17.33(16.12-19.59)	18.17(14.77-21.3)	16.4(14.81-18.59)
HPV prevalence among total population (2010)	0.27(0.27-0.27)	0.27(0.27-0.27)	0.27(0.27-0.27)	0.27(0.27-0.27)
HPV prevalence among total population (2017)	0.26(0.26-0.26)	0.26(0.26-0.26)	0.26(0.26-0.26)	0.26(0.26-0.26)
Relative risk (HPV prevalence, 2010)	1.16(1.1-1.2)	1.29(1.24-1.34)	1.22(1.15-1.27)	1.23(1.17-1.31)
Relative risk (HPV prevalence, 2017)	1.11(1.05-1.23)*^	1.41(1.32-1.49)*+^	1.24(1.16-1.33)*+	1.25(1.17-1.33)*+
Cumulative new cancer incidence among HIV+ over year 2008-2017 (per 100, 000 persons)	NA(-)	NA(-)	NA(-)	NA(-)

Cumulative new cancer incidence among HIV- over year 2008-2017 (per 100, 000	NA(-)	NA(-)	NA(-)	NA(-)
Relative risk (cumulative cancer incidence over year 2008-2017)	NA(-)	NA(-)	NA(-)	NA(-)

440 NA: we did not model cancers in HETM

441 \* indicates significant compared to relative risk = 1

442 + indicates significant compared to "no biological risk" within same intervention assumption

443 ^ indicates significant compared to 2010 estimates where HIV burden was lower

444 † indicates significant compared to "prescreening"

445 The criterion for significance is p < 0.05.

446

# 447 Table 2b: Numerical analyses of HIV and HPV disease burden and relevant network

### 448 metrics under "screening only" assumption (HETM)

449

	Screening only			
	No biological risk	All increased risk	Increased risk of progression	Increased risk of HPV acquisition
Average degree for HIV+	13.21(11.58-14.99)	13.44(12.05-14.16)	13.28(12.16-14.15)	13.43(12.09-14.37)
Average degree for overall population	17.25(17.25-17.25)	17.25(17.25-17.25)	17.25(17.25-17.25)	17.25(17.25-17.25)
Average degree for HPV+	25.41(25.41-25.41)	25.41(25.4-25.41)	25.41(25.41-25.41)	25.41(25.4-25.41)
Average degree or HIV+ and HPV+	17.23(14.25-19.05)	17.4(13.36-19.82)	17.16(15.37-18.79)	17.23(14.56-19.01)
HPV prevalence among total population (2010)	0.27(0.27-0.27)	0.27(0.27-0.27)	0.27(0.27-0.27)	0.27(0.27-0.27)
HPV prevalence among total population (2017)	0.26(0.26-0.26)	0.26(0.26-0.26)	0.26(0.26-0.26)	0.26(0.26-0.26)
Relative risk (HPV prevalence, 2010)	1.15(1.09-1.21)	1.31(1.25-1.36)	1.21(1.16-1.29)	1.27(1.18-1.38)
Relative risk (HPV prevalence, 2017)	1.13(0.99-1.25)*	1.45(1.4-1.48)*+^	1.25(1.2-1.32)*+^	1.27(1.15-1.42)*+
Cumulative new cancer incidence among HIV+ over year 2008-2017 (per 100, 000 persons)	NA(-)	NA(-)	NA(-)	NA(-)
Cumulative new cancer incidence among HIV- over year 2008-2017 (per 100, 000 persons)	NA(-)	NA(-)	NA(-)	NA(-)
Relative risk (cumulative cancer incidence over year 2008-2017)	NA(-)	NA(-)	NA(-)	NA(-)

450 NA: we did not model cancers in HETM

- 451 \* indicates significant compared to relative risk = 1
- 452 + indicates significant compared to "no biological risk" within same intervention assumption
- 453 ^ indicates significant compared to 2010 estimates where HIV burden was lower
- 454 *†* indicates significant compared to "prescreening"
- 455 The criterion for significance is p < 0.05.
- 456

### 457 Table 2c: Numerical analyses of HIV and HPV disease burden and relevant network

### 458 metrics under "status quo" assumption (HETM)

	Status quo			
	No biological risk	All increased risk	Increased risk of progression	Increased risk of HPV acquisition
Average degree for HIV+	13.03(12.62-14.59)	12.85(11.93-14.81)	13.4(11.33-15.1)	13.48(12.35-15.17)
Average degree for overall population	17.25(17.25-17.25)	17.25(17.25-17.25)	17.25(17.25-17.25)	17.25(17.25-17.25)
Average degree for HPV+	25.46(25.46-25.46)	25.45(25.45-25.46)	25.46(25.45-25.46)	25.46(25.45-25.46)
Average degree or HIV+ and HPV+	17.53(15.75-21.03)	16.66(14.7-20.28)	17.67(13.36-20.53)	17.47(15.41-19.72)
HPV prevalence among total population (2010)	0.27(0.27-0.27)	0.27(0.27-0.27)	0.27(0.27-0.27)	0.27(0.27-0.27)
HPV prevalence among total population (2017)	0.26(0.26-0.26)	0.26(0.26-0.26)	0.26(0.26-0.26)	0.26(0.26-0.26)
Relative risk (HPV prevalence, 2010)	1.17(1.14-1.21)	1.36(1.32-1.38)	1.22(1.19-1.28)	1.26(1.2-1.31)
Relative risk (HPV prevalence, 2017)	1.13(1.01-1.16)*^	1.46(1.41-1.54)*+^	1.25(1.13-1.34)*+	1.32(1.22-1.39)*+^†
Cumulative new cancer incidence among HIV+ over year 2008-2017 (per 100, 000 persons)	NA(-)	NA(-)	NA(-)	NA(-)
Cumulative new cancer incidence among HIV- over year 2008-2017 (per 100, 000 persons)	NA(-)	NA(-)	NA(-)	NA(-)
Relative risk (cumulative cancer incidence over year 2008-2017)	NA(-)	NA(-)	NA(-)	NA(-)

459 NA: we did not model cancers in HETM

460 \* indicates significant compared to relative risk = 1

461 + indicates significant compared to "no biological risk" within same intervention assumption

462 ^ indicates significant compared to 2010 estimates where HIV burden was lower

463 † indicates significant compared to "prescreening"

464 The criterion for significance is p < 0.05.

465

# 466 Table 3a: Numerical analyses of HIV and HPV disease burden and relevant network

467 metrics under "prescreening" assumption (MSM)

	Prescreening			
	No biological risk	All increased risk	Increased risk of progression	Increased risk of HPV acquisition
Average degree for HIV+	25.57(24.93-26.38)	25.61(24.81-26.54)	25.61(25.03-26.24)	25.56(24.57-26.29)
Average degree for overall population	19.7(19.63-19.82)	19.71(19.6-19.84)	19.7(19.64-19.79)	19.71(19.65-19.81)
Average degree for HPV+	28.67(28.54-28.8)	28.84(28.64-29.08)	28.86(28.58-29.11)	28.65(28.44-28.85)
Average degree or HIV+ and HPV+	34.67(33.2-35.35)	34.88(33.11-35.59)	35.63(33.77-37.22)	33.88(32.65-34.94)
HPV prevalence among total population (2010)	0.28(0.28-0.28)	0.29(0.29-0.29)	0.28(0.28-0.28)	0.28(0.28-0.28)
HPV prevalence among total population (2017)	0.27(0.27-0.27)	0.29(0.28-0.29)	0.27(0.27-0.27)	0.28(0.28-0.28)
Relative risk (HPV prevalence, 2010)	1.25(1.23-1.29)	1.43(1.41-1.44)	1.28(1.26-1.32)	1.36(1.33-1.38)
Relative risk (HPV prevalence, 2017)	1.33(1.31-1.37)*^	1.62(1.58-1.66)*+^	1.41(1.39-1.44)*+^	1.51(1.47-1.54)*+^
Cumulative new cancer incidence among HIV+ over year 2008-2017 (per 100, 000 persons)	750.74(605.91- 906.12)	2086.12(1833.14- 2418.83)	2166.61(1755.57- 2342.04)	829.67(618.48- 948.46)
Cumulative new cancer incidence among HIV- over year 2008-2017 (per 100, 000 persons)	530.04(528.17- 531.6)	529.72(528.25- 531.62)	530.49(528.08- 532.14)	530.21(528.64- 531.88)
Relative risk (cumulative cancer incidence over year 2008-2017)	1.42(1.14-1.72)*	3.94(3.47-4.57)*+	4.08(3.31-4.41)*+	1.56(1.16-1.79)*

469 \* indicates significant compared to relative risk = 1

470 + indicates significant compared to "no biological risk" within same intervention assumption

471 ^ indicates significant compared to 2010 estimates where HIV burden was lower

472 *†* indicates significant compared to "prescreening"

473 The criterion for significance is p < 0.05.

474

### 475 Table 3b: Numerical analyses of HIV and HPV disease burden and relevant network

### 476 metrics under "screening only" assumption (MSM)

	Screening only			
	No biological risk	All increased risk	Increased risk of progression	Increased risk of HPV acquisition
Average degree for HIV+	25.6(24.74-26.4)	25.52(24.66-26.33)	25.44(24.75-26.07)	25.77(25.22-26.22)

Average degree for overall population	19.7(19.63-19.8)	19.72(19.63-19.81)	19.71(19.64-19.79)	19.72(19.65-19.86)
Average degree for HPV+	28.82(28.67-29.04)	28.93(28.77-29.08)	29.04(28.88-29.19)	28.72(28.47-28.9)
Average degree or HIV+ and HPV+	35.17(33.73-36.31)	34.52(33.11-35.24)	35.67(34.46-36.31)	33.97(32.84-34.94)
HPV prevalence among total population (2010)	0.27(0.27-0.27)	0.28(0.28-0.28)	0.27(0.27-0.27)	0.27(0.27-0.27)
HPV prevalence among total population (2017)	0.26(0.26-0.26)	0.28(0.28-0.28)	0.26(0.26-0.27)	0.27(0.27-0.27)
Relative risk (HPV prevalence, 2010)	1.26(1.23-1.28)	1.47(1.43-1.5)	1.3(1.27-1.35)	1.39(1.35-1.42)
Relative risk (HPV prevalence, 2017)	1.33(1.3-1.37)*^	1.7(1.67-1.75)*+^†	1.46(1.43-1.49) *+^†	1.53(1.49-1.56)*+^
Cumulative new cancer				
incidence among HIV+ over	227.32(163.79-	799.15(624.49-	753.07(592.56-	232.1(149.53-
year 2008-2017 (per 100, 000	284.84)	977.45)	980.78)	332.22)
persons)				
Cumulative new cancer				
incidence among HIV- over	167.37(166.45-	167.12(166.5-	166.96(166.17-	166.98(165.74-
year 2008-2017 (per 100, 000 persons)	168.31)	167.79)	168.31)	167.78)
Relative risk (cumulative				
cancer incidence over year 2008-2017)	1.36(0.97-1.7)*	4.78(3.74-5.86) <sup>*+†</sup>	4.51(3.56-5.9)*+	1.39(0.9-1.98)

477 \* indicates significant compared to relative risk = 1

478 + indicates significant compared to "no biological risk" within same intervention assumption

479 ^ indicates significant compared to 2010 estimates where HIV burden was lower

480 *†* indicates significant compared to "prescreening"

481 The criterion for significance is p < 0.05.

482

### 483 Table 3c: Numerical analyses of HIV and HPV disease burden and relevant network

### 484 metrics under "status quo" assumption (MSM)

	Status quo			
	No biological risk	All increased risk	Increased risk of progression	Increased risk of HPV acquisition
Average degree for HIV+	25.99(25.48-26.47)	25.7(25.28-26.11)	25.8(25.03-26.56)	25.65(25.07-26.25)
Average degree for overall population	19.76(19.68-19.83)	19.76(19.68-19.8)	19.72(19.62-19.82)	19.71(19.63-19.79)
Average degree for HPV+	29.01(28.9-29.28)	29.02(28.82-29.09)	29.06(28.83-29.29)	28.76(28.47-28.96)
Average degree or HIV+ and HPV+	35.98(35.51-37.67)	34.64(33.53-35.34)	35.86(34.25-37.02)	34.07(32.7-34.82)
HPV prevalence among total population (2010)	0.27(0.27-0.27)	0.28(0.28-0.28)	0.27(0.27-0.27)	0.27(0.27-0.27)
HPV prevalence among total population (2017)	0.26(0.26-0.26)	0.28(0.27-0.28)	0.26(0.26-0.26)	0.27(0.27-0.27)
Relative risk (HPV prevalence, 2010)	1.27(1.26-1.29)	1.48(1.45-1.52)	1.31(1.29-1.34)	1.38(1.36-1.42)

Relative risk (HPV prevalence, 2017)	1.36(1.34-1.38)*^	1.74(1.68-1.75)*+^†	1.47(1.42-1.52)*+^†	1.53(1.48-1.56) *+^	
Cumulative new cancer					
incidence among HIV+ over	224.31(160.82-	871.64(856.1-	752.94(530.12-	207.36(119.82-	
year 2008-2017 (per 100, 000	294.46)	880.56)	845.96)	278.32)	
persons)					
Cumulative new cancer					
incidence among HIV- over	167.5(166.54-	167.31(166.78-	166.92(165.79-	166.99(166.27-	
year 2008-2017 (per 100, 000	167.99)	167.8)	167.72)	168.03)	
persons)					
Relative risk (cumulative					
cancer incidence over year	1.34(0.95-1.75)	5.21(5.12-5.25)*+ <sup>†</sup>	4.51(3.18-5.06)*+†	1.24(0.72-1.66)	
2008-2017)					

\* indicates significant compared to relative risk = 1

486 + indicates significant compared to "no biological risk" within same intervention assumption

487 ^ indicates significant compared to 2010 estimates where HIV burden was lower

488 *†* indicates significant compared to "prescreening"

489 The criterion for significance is p < 0.05.

490

491 The differences in  $RP_{HPV}$  could be explained through differences in the average degree in

492 persons with HIV  $(d_{HIV+})$ , average degree in persons with HPV  $(d_{HPV+})$ , and average degree in

493 the total population ( $d_{overall}$ ) (Table 1c, 2c, 3c). For HETF and MSM,  $d_{HIV+}$  (HETF: 23, MSM:

494 25) and  $d_{HPV+}$  (HETF: 19, MSM: 29) were significantly higher than  $d_{overall}$  (HETF: 13, MSM:

495 20). However, for HETM,  $d_{HPV+}(25)$  was higher than  $d_{overall}$  (17) but  $d_{HIV+}(13)$  was lower

496 than  $d_{overall}$  (17). These results, as expected, suggest that if both HIV and HPV infections are

497 concentrated in higher degree networks, then the  $RP_{HPV}$  is greater than 1. For HETM, although

498 HPV was concentrated in higher degree networks, as the prevalence of HIV is very low, it was

499 more randomly spread in the network, thus the  $RP_{HPV}$  was closer to 1. For HETF, compared to

500 MSM, as HIV prevalence was moderately low, infections were focused on higher degree

501 networks,  $d_{HIV+}/d_{overall}$  was 1.77 for HETF compared to 1.25 for MSM. These results point to

502 the sensitivity of  $RR_{HPV}$  to disease burden of both diseases and the role of network dynamics.

503

504 For all three transmission-groups and across all intervention scenarios, compared to 'no

biological risk',  $RP_{HPV}$  was significantly higher in each of the three biological risk assumptions,

506 lowest in 'increased risk of HPV acquisition' scenario, and highest increase in 'all increased risk'

507 (increased risk of progression and HPV acquisition) scenario. For example, for 'status quo'

508 intervention, the  $RP_{HPV}$  in 'all increased risk' was 1.67 (1.64-1.71) for HETF, 1.46 (1.41-1.54)

509 for HETM, and 1.74 (1.68-1.75) for MSM (Table 1c, 2c and 3c, respectively). Whereas, for the

same 'status quo' intervention, the  $RP_{HPV}$  in 'no biological risk' was 1.41(1.36-1.44) for HETF,

511 1.13(1.01-1.16) for HETM, and 1.36(1.34-1.38) for MSM. While the values under 'no biological
512 risk' are attributable to behavioral factors, the differences between 'all increased risk' and 'no
513 biological risk' are attributable to biological factors of coinfection.

514

515 The values of  $RP_{HPV}$  were sensitive to HIV prevalence, as seen by higher values in year 2017 516 compared to year 2010 for both 'no biological risk' and 'all increased risk'. To note here that 517 though HIV prevalence increased over this period, HIV care also increased (e.g., proportion on 518 treatment with viral suppression increased from 39% in 2010 to 56% in 2017), and thus, new 519 HIV cases were further concentrated in higher degree networks. Thus, the values of  $RR_{HPV}$  in 2017 were higher than in 2010. Further, while the fraction of increased HPV prevalence 520 521 attributed to biological factors were 22%, 52%, and 43% for HETF, HETM, and MSM, 522 respectively, in 2010, they increased to 38%, 71%, and 51% in 2017. This is as expected because 523 the dynamics of network can amplify the overall disease risk. Thus, we can expect the fraction

524 attributed to biological risk to also be sensitive to the network dynamics.

525

526 Relative incidence of cervical cancer  $(RI_{cancer})$  in 'status-quo' intervention scenario was greater than 1, and it was significantly higher in 'all increased risk' (3.6(1.31-6.17)) compared to 'no 527 528 biological risk' (1.51(0.72-2.81)) (Table 1c). That is, under the assumptions used in this study, 529 observed cases of cervical cancer incidence among women with HIV would be about 3.6 times 530 higher than among women without HIV, about 80% of the burden attributed to biological factors 531 and the remaining attributable to behavioral factors. Under the 'all increased risk' scenario, 532 values of *RI<sub>cancer</sub>* were slightly higher under 'status-quo' (3.6(1.31-6.17)) (Table 1c) compared 533 to 'prescreening' (2.86(1.77-4.8)) (Table 1a), suggesting that, if screening were kept similar 534 between women with and without HIV, the cervical cancer burden gap between them would 535 widen. To note here, due to lack of data, we assumed screening and vaccine uptakes to be similar 536 among persons with HIV and without HIV, although this may not be the case.

537

538 Similar results were observed for cancers among MSM (Table 3a - 3c). *RI*<sub>cancer</sub> in 'all increased

risk' was significantly greater than 1 in each of the three intervention scenarios, 2.83(2.33-3.51)

540 in 'prescreening', 3.89(2.91-4.89) in 'screening only', and 4.03(3.49-4.31) in 'status-quo'.

541 *RI<sub>cancer</sub>* in 'all increased risk' were also significantly greater than 'no biological risk' within

542 each of the three intervention scenarios. To recollect that to model anal cancer among MSM, we

543 utilized the same disease progression model as cervical cancer, for purposes of sensitivity

analyses on relative risk metrics. Under this context, collectively, our results suggest higher risk

545 of cancer among persons with HIV compared to persons without HIV, most attributed to

- 546 biological risk [11–13], and a smaller but significant fraction attributed to behavioral factors.
- 547

# 548 Discussion and Conclusions

549 We demonstrate the feasibility of application of a new MAC framework for jointly simulating

550 diseases of varying prevalence but with common modes of transmission. Using the same network

and sexual behavior, modeled at the individual-level for HIV and aggregated-level for HPV, the

model was able to replicate both HIV and HPV in the U.S. population, and thus serves as proof-

- 553 of-concept of the MAC simulation technique.
- 554

555 Estimates of  $RP_{HPV}$  in the literature are sparse, and not available for the U.S. population in recent 556 times.  $RP_{HPV}$  estimates from our model, of 1.67 (1.64-1.71) among women in 'all increased risk, 557 status quo' scenario, is similar to that in an observational study in the literature on an Italian 558 population (1.71) [16], and lower than that in an observational study on a South African 559 population (1.9) [14]. To note here that HPV prevalence and HIV prevalence are higher in South 560 Africa than in the U.S. and European populations. A national study of HIV infection among 561 adolescent girls in the U.S. conducted in 1996-97 [15], reported a RP<sub>HPV</sub> of 3.3 (1.6-6.7). RP<sub>HPV</sub> 562 estimates from our model among adolescent girls (13-18 yrs) in the 'all increased risk,

563

564

565 Our model estimates for  $RI_{cancer}$  in 'all increased risk, status quo' scenario (3.6(1.31-6.17)), is

prescreening' scenario is 2.89 (1.41-6.1), and thus compares well with the national study.

similar to that in large population-based observational studies conducted on the U.S. population,

567 3.80 (3.48-4.15) in [19] and 4.1(2.3-6.6) in [29]. A recent global systematic review of cervical

568 cancer reported a higher value of 5.34 (3.80-7.51) among high-income countries [18], suggesting

- 569 likely differences across populations and study settings. Similarity in our model results with
- 570 observational studies provides general model validity. To note here that the results are influenced
- 571 by the assumptions used for modeling biological risk (Appendix Table S2), that were based on
- 572 estimates in the literature [47,77,78]. Above results suggest that the literature estimates are a

good fit, however, considering the sensitivity of the relative risk metrics and the fractions
attributed to biological risk to disease burdens, closer calibrations specific to the population and
timeline of interest can be conducted during implementation of the model for decision analyses.

577 Relative prevalence of HPV was greater than 1 in 'no biological risk' and 'all increased risk', 578 values in 'all increased risk' being higher than 'no biological risk'. Further, in 'all increased risk, 579 status-quo' scenario, relative incidence of cervical cancer was much higher than HPV. Similar 580 patterns were observed for cancers and HPV among MSM. These results suggest that behavioral 581 factors contribute to increased risk of HIV-HPV coinfection and are further exacerbated by 582 biological factors, especially for cancer cases. These results suggest the need for both behavioral 583 interventions to reduce the risk for infection, and care interventions for early detection and 584 treatment of HPV to reduce the risk of cancers. Social factors are among key drivers of increased 585 risky behavior e.g., higher number of partners and higher condomless sex, or lower adherence to 586 treatment that prevents transmission by suppressing viral load [36–39]. Thus, structural 587 interventions such as healthcare coverage, subsidized housing and food programs, and access to 588 mental healthcare [42–45,83], are key part of behavioral interventions.

589

590 Model estimates of relative prevalence and fraction attributable to each factor (biological and 591 behavioral) varied with HIV burden and care, suggesting influence of network dynamics, as 592 verified by the average degree estimates. Model estimates of relative incidence of cervical cancer 593 was higher in the HPV/ cancer screening scenario compared to the pre-screening scenario, 594 suggesting sensitivity to HPV burden and care. Thus, jointly modeling diseases in a dynamic 595 network model can help more accurately measure the impact of interventions. Above results also 596 support the need for more focused screening among persons with HIV (Note here that, to 597 evaluate the sensitivity to changes in interventions, our model assumed same levels of screening 598 among persons with and without HIV).

599

600 Our work is subject to limitations. We only focused on a general model-fit for HPV among

601 women and did not conduct detailed sensitivity analyses for the robustness of the calibration

method. Though the overall HPV model provided a good fit in most metrics in the pre-screening

results (Fig 2 and Fig 3a), the results under the screening scenario (Fig 3b) were not always same

604 as surveillance estimates. As post-screening model fits are largely influenced by assumptions for 605 age-specific compliance to screening, and not disease epidemiology, considering the scope of our 606 analyses we did not attempt to calibrate screening rates. Further, due to unavailability of more 607 recent data on screening rates, we kept it constant at the 2006 data assumptions for years 2006 to 608 2017. These assumptions are acceptable because, as noted earlier, per surveillance data, there 609 were minor changes in cervical cancer incidence and mortality over the period 2006 to 2017. We 610 did not attempt to calibrate biological risk multipliers but used estimates from the literature. 611 Though the model outcomes of relative risk were in the range of that reported from observational 612 studies, considering its sensitivity to disease burden and care changes over time, during 613 implementation of model to inform decisions it should be specifically calibrated to the 614 population under study. For MSM, we did not specifically model anal cancer (the sequelae of 615 most concern) but assumed similar epidemiology to cervical cancer. As observations here justify 616 the need for jointly modeling diseases, as opposed to independent disease models, adding anal 617 cancer in future work would be a suitable extension. We only evaluated the increased risk of 618 HPV among persons with HIV and did not evaluate vice-versa.

619

620 We believe the overall validation of HIV and HPV serves as proof-of-concept of the MAC 621 framework for joint modeling related diseases with widely varying prevalence but spread on a 622 common network. The model can be expanded to include other STIs. As numerical analyses 623 suggest, disease interactions are attributed to both behavioral factors and biological factors. 624 Structural interventions that address social determinants are a key part of behavioral 625 interventions. The MAC framework is suitable for modeling behaviors as a function of social 626 determinants, and further, measuring the impact of structural interventions on prevention of 627 overall STI burden. The network features of the MAC framework are suitable for network-based 628 analyses of interventions such as cluster detection and response, that has been successful in 629 identifying populations with high HIV transmission [59,84]. Expanding HIV cluster-based 630 network detection to joint-disease framework could help identify populations most vulnerable to 631 diseases, their intervention needs, and collectively evaluate the impact of intervention on overall 632 disease prevention.

633 Our model is also suitable for joint modeling of sub-populations with widely varying disease 634 burden, but who interact with each other, such as HETF, HETM, and MSM in this case study. 635 Recent studies highlight the high burden of HPV-related clinical conditions among HIV infected 636 MSM [2,85,86], but there are only few models in this area [87]. Further, they model MSM in 637 isolation. The computational tractability of the MAC simulation technique makes joint modeling 638 sub-populations with widely vary prevalence feasible. HIV burden is disproportionately higher 639 among MSM in the U.S. [82], and there are significant associations of HIV infections among HETF from mixing with MSM [56,57], which is also relevant in the context of higher burden of 640 641 cervical cancer among women with HIV. Thus, simulation of interactions between sub-642 populations and between diseases can more accurately represent the dynamics of infection 643 spread. Behaviors leading to transmission across these sub-groups are driven by social stressors 644 and socio-economic vulnerability and are typically exacerbated in neighborhoods of high poverty [88,89]. Therefore, the model developed here would be suitable for jointly evaluating 645 646 combinations of structural and disease-specific interventions, across sub-population groups, and 647 across multiple diseases. Simulating these in a national context could help inform broader public 648 health policies.

650	Re	ferences
651	[1]	Braaten KP, Laufer MR. Human Papillomavirus (HPV), HPV-Related Disease, and
652		the HPV Vaccine. Rev Obstet Gynecol. 2008;1:2–10.
653	[2]	Ye Y, Burkholder GA, Wiener HW, et al. Comorbidities associated with HPV
654		infection among people living with HIV-1 in the southeastern US: a retrospective
655		clinical cohort study. BMC Infect Dis. 2020;20:144.
656	[3]	Franco EL, Duarte-Franco E, Ferenczy A. Cervical cancer: epidemiology, prevention
657		and the role of human papillomavirus infection. CMAJ. 2001;164:1017–1025.
658	[4]	Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human
659		papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–265.
660	[5]	Bosch FX, Manos MM, Munoz N, et al. Prevalence of Human Papillomavirus in
661		Cervical Cancer: a Worldwide Perspective. JNCI Journal of the National Cancer
662		Institute. 1995;87:796–802.
663	[6]	de Martel C, Georges D, Bray F, et al. Global burden of cancer attributable to
664		infections in 2018: a worldwide incidence analysis. Lancet Glob Health.
665		2020;8:e180–e190.
666	[7]	Grulich AE, Jin F, Conway EL, et al. Cancers attributable to human papillomavirus
667		infection. Sex Health. 2010;7:244.
668	[8]	Chaturvedi AK. Beyond Cervical Cancer: Burden of Other HPV-Related Cancers
669		Among Men and Women. Journal of Adolescent Health. 2010;46:S20–S26.
670	[9]	Chaturvedi AK, Engels EA, Pfeiffer RM, et al. Human Papillomavirus and Rising
671		Oropharyngeal Cancer Incidence in the United States. Journal of Clinical Oncology.
672		2011;29:4294–4301.
673	[10]	Viens LJ, Henley SJ, Watson M, et al. Human Papillomavirus-Associated Cancers
674		— United States, 2008–2012. 2016.
675	[11]	Ferenczy A, Coutlée F, Franco E, et al. Human papillomavirus and HIV coinfection
676		and the risk of neoplasias of the lower genital tract: a review of recent developments.
677		CMAJ. 2003;169:431–434.
678	[12]	Medford RJ, Salit IE. Anal cancer and intraepithelial neoplasia: epidemiology,
679		screening and prevention of a sexually transmitted disease. Can Med Assoc J.
680		2015;187:111–115.
681	[13]	Robbins HA, Pfeiffer RM, Shiels MS, et al. Excess Cancers Among HIV-Infected
682		People in the United States. JNCI: Journal of the National Cancer Institute. 2015;107.
683	[14]	Taku O, Businge CB, Mdaka ML, et al. Human papillomavirus prevalence and risk
684		factors among HIV-negative and HIV-positive women residing in rural Eastern Cape,
685		South Africa. International Journal of Infectious Diseases. 2020;95:176–182.
686	[15]	Moscicki A-B, Ellenberg JH, Vermund SH, et al. Prevalence of and Risks for
687		Cervical Human Papillomavirus Infection and Squamous Intraepithelial Lesions in
688		Adolescent Girls. Arch Pediatr Adolesc Med. 2000;154:127.
689	[16]	Tartaglia E, Falasca K, Vecchiet J, et al. Prevalence of HPV infection among HIV-
690		positive and HIV-negative women in Central/Eastern Italy: Strategies of prevention.
691		Oncol Lett. 2017;14:7629–7635.
692	[17]	Abraham AG, D'Souza G, Jing Y, et al. Invasive Cervical Cancer Risk Among HIV-
693		Infected Women. JAIDS Journal of Acquired Immune Deficiency Syndromes.
694		2013;62:405–413.

695	[18]	Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical
696		cancer associated with HIV. Lancet Glob Health. 2021;9:e161-e169.
697	[19]	Stier EA, Engels E, Horner M-J, et al. Cervical cancer incidence stratified by age in
698		women with HIV compared with the general population in the United States, 2002–
699		2016. AIDS. 2021;35:1851–1856.
700	[20]	Bower M, Mazhar D, Stebbing J. Should Cervical Cancer Be an Acquired
701		Immunodeficiency Syndrome–Defining Cancer? Journal of Clinical Oncology.
702		2006;24:2417–2419.
703	[21]	Stanley MA. Sterling JC. Host Responses to Infection with Human Papillomavirus.
704		2014. p. 58–74.
705	[22]	Ahdieh L, Klein RS, Burk R, et al. Prevalence, Incidence, and Type-Specific
706		Persistence of Human Papillomavirus in Human Immunodeficiency Virus (HIV)–
707		Positive and HIV-Negative Women, J Infect Dis. 2001:184:682–690.
708	[23]	Phelan DF. Gange SI, Ahdieh-Grant L, et al. Determinants of Newly Detected
709	[=0]	Human Papillomavirus Infection in HIV-Infected and HIV-Uninfected Injection
710		Drug Using Women Sex Transm Dis 2009:36:149–156
711	[24]	Xie X. Strickler HD. Xue X. Additive Hazard Regression Models: An Application to
712	[]	the Natural History of Human Papillomavirus. Comput Math Methods Med
713		2013·2013·1–7
714	[25]	Dev D L o Y Ho GYF et al Incidence of and Risk Factors for Genital Human
715	[=0]	Papillomavirus Infection in Women Drug Users, JAIDS Journal of Acquired Immune
716		Deficiency Syndromes 2006:41:527–529
717	[26]	Abdieh L. Munoz A. Vlahov D. et al. Cervical Neoplasia and Repeated Positivity of
718	[20]	Human Papillomavirus Infection In Human Immunodeficiency Virus-seropositive
719		and -seronegative Women Am I Enidemiol 2000:151:1148–1157
720	[27]	Rowhani-Rahbar A. Hawes SE. Sow PS, et al. The Impact of HIV Status and Type
721	[_,]	on the Clearance of Human Papillomavirus Infection among Senegalese Women J
722		Infect Dis 2007:196:887–894
723	[28]	Safaeian M. Kiddugavu M. Gravitt PE. et al. Determinants of incidence and
724	[]	clearance of high-risk human papillomavirus infections in rural Rakai. Uganda
725		Cancer Epidemiol Biomarkers Prev. 2008:17:1300–1307.
726	[29]	Abraham AG, D'Souza G, Jing Y, et al. Invasive cervical cancer risk among HIV-
727	[=>]	infected women: a North American multicohort collaboration prospective study J
728		Acquir Immune Defic Syndr. 2013:62:405–413
729	[30]	Adler DH Kakinami I. Modisenvane T et al Increased regression and decreased
730	[30]	incidence of human nanillomavirus-related cervical lesions among HIV-infected
731		women on HAART AIDS 2012.26.1645–1652
732	[31]	Clifford GM Franceschi S Keiser O et al Immunodeficiency and the risk of
733	[31]	cervical intraenithelial neonlasia 2/3 and cervical cancer. A nested case-control study
734		in the Swiss HIV cohort study. Int I Cancer 2016:138:1732–1740
735	[32]	Massad I S Abdieb I Benning I et al Evolution of cervical abnormalities among
736	[32]	women with HIV-1: evidence from surveillance cytology in the women's interagency
737		HIV study I Acquir Immune Defic Syndr 2001.27.432_442
738	[33]	Six C Heard I Bergeron C et al Comparative prevalence incidence and short term
739	[33]	prognosis of cervical squamous intraepithelial lesions amongst HIV-positive and
740		HIV_negative women AIDS 1008.12.1047 1056
/+0		111  v-inegative wollien. Allos. 1770,12.10+7=1030.

741	[34]	Whitham HK, Hawes SE, Chu H, et al. A Comparison of the Natural History of HPV
742		Infection and Cervical Abnormalities among HIV-Positive and HIV-Negative
743		Women in Senegal, Africa. Cancer Epidemiol Biomarkers Prev. 2017;26:886–894.
744	[35]	Zeier MD, Botha MH, van der Merwe FH, et al. Progression and persistence of low-
745		grade cervical squamous intraepithelial lesions in women living with human
746		immunodeficiency virus. J Low Genit Tract Dis. 2012:16:243–250.
747	[36]	Craddock IB, Barman-Adhikari A, Combs KM, et al. Individual and Social Network
748	[50]	Correlates of Sexual Health Communication Among Youth Experiencing
749		Homelessness AIDS Behav 2020:24:222–232
750	[37]	Henwood BF Rhoades H Redline B et al Risk behaviour and access to HIV/AIDS
751	[37]	prevention services among formerly homeless young adults living in housing
752		programmes AIDS Care 2020:32:1457_1461
752	[38]	Santa Maria D. Daundasakara SS. Harnandaz DC. at al. Savual risk classes among
753	[30]	youth experiencing homelessness: Palation to childhood advarcition current montal
755		symptoms, substance use, and HIV testing, DL oS One, 2020;15:e0227221
755	[20]	Edidin ID, Conim 7, Hunter SL et al. The Montel and Dhysical Health of Homeless
750	[39]	Vouth, A. Litaratura Daviau, Child Bauchistry, Llura, Dav. 2012;42:254, 275
151	F 4 0 1	I outil: A Literature Review. Child Psychiatry Hull Dev. 2012;45:554–575.
750	[40]	Huang T-LA, Frazier EL, Sansoni SL, et al. Nearly Han OI US Adults Living with HUV Deseived Enders Dissbility Denefits In 2000, Health Aff. 2015;24:1657–1665
759	F / 1 1	HIV Received Federal Disability Benefits In 2009. Health All. 2015;54:1057–1005.
/60	[41]	Centers for Disease Control and Prevention. Benavioral and Clinical Characteristics
/61		of Persons Living with Diagnosed HIV Infection—Medical Monitoring Project,
762		United States, 2018 Cycle (June 2018-May 2019). HIV Surveillance Special Report
763		[Internet]. 2018 [cited 2022 Dec 20];25. Available from:
764	5 4 6 7	http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
765	[42]	Adimora AA, Auerbach JD. Structural interventions for HIV prevention in the
766	5 ( 0 7	United States. J Acquir Immune Defic Syndr. 2010;55 Suppl 2:S132-5.
767	[43]	Blankenship KM, Friedman SR, Dworkin S, et al. Structural Interventions: Concepts,
768		Challenges and Opportunities for Research. Journal of Urban Health. 2006;83:59–72.
769	[44]	Blankenship KM, Bray SJ, Merson MH. Structural interventions in public health.
770		AIDS. 2000;14:S11–S21.
771	[45]	Sipe TA, Barham TL, Johnson WD, et al. Structural Interventions in HIV Prevention:
772		A Taxonomy and Descriptive Systematic Review. AIDS Behav. 2017;21:3366–3430.
773	[46]	Hall MT, Smith MA, Simms KT, et al. The past, present and future impact of HIV
774		prevention and control on HPV and cervical disease in Tanzania: A modelling study.
775		PLoS One. 2020;15:e0231388.
776	[47]	Tan N, Sharma M, Winer R, et al. Model-estimated effectiveness of single dose 9-
777		valent HPV vaccination for HIV-positive and HIV-negative females in South Africa.
778		Vaccine. 2018;36:4830–4836.
779	[48]	Campos NG, Mvundura M, Jeronimo J, et al. Cost-effectiveness of HPV-based
780		cervical cancer screening in the public health system in Nicaragua. BMJ Open.
781		2017;7.
782	[49]	Perez-Guzman PN, Chung MH, de Vuyst H, et al. The impact of scaling up cervical
783		cancer screening and treatment services among women living with HIV in Kenya: a
784		modelling study. BMJ Glob Health. 2020;5:e001886.
785	[50]	Liu G, Mugo NR, Bayer C, et al. Impact of catch-up human papillomavirus
786	-	vaccination on cervical cancer incidence in Kenya: A mathematical modeling

787		evaluation of HPV vaccination strategies in the context of moderate HIV prevalence.
788		EClinicalMedicine. 2022;45:101306.
789	[51]	Gopalappa C., Balasubramanian H., J. Haas P. A new mixed agent-based network
790		and compartmental simulation framework for joint modeling of related infectious
791		diseases- Application to sexually transmitted infections. Infectious Disease Modeling
792		(in-press).
793	[52]	Smieszek T, Fiebig L, Scholz RW. Models of epidemics: when contact repetition and
794		clustering should be included. Theor Biol Med Model. 2009;6:11.
795	[53]	Centers for Disease Control and Prevention. Estimated HIV incidence and prevalence
796		in the United States, 2015–2019. HIV Surveillance Supplemental Report 2021
797		[Internet]. 2021 [cited 2022 Dec 20];26. Available from:
798		http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
799	[54]	Stelzle D, Tanaka LF, Lee KK, et al. Estimates of the global burden of cervical
800		cancer associated with HIV. Lancet Glob Health. 2021;9:e161-e169.
801	[55]	Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the Population Sizes of Men
802		Who Have Sex With Men in US States and Counties Using Data From the American
803		Community Survey. JMIR Public Health Surveill. 2016;2:e14.
804	[56]	Gopalappa C, Farnham PG, Chen YH, et al. Progression and Transmission of
805		HIV/AIDS (PATH 2.0): A New, Agent-ased Model to Estimate HIV Transmissions
806		in the United States. Medical Decision Making. 2016;37:224-233.
807	[57]	Oster AM, Wertheim JO, Hernandez AL, et al. Using Molecular HIV Surveillance
808		Data to Understand Transmission Between Subpopulations in the United States.
809		JAIDS Journal of Acquired Immune Deficiency Syndromes. 2015;70:444–451.
810	[58]	Eden M, Castonguay R, Munkhbat B, et al. Agent-based evolving network modeling:
811		a new simulation method for modeling low prevalence infectious diseases. Health
812		Care Manag Sci. 2021;24:623–639.
813	[59]	Singh S, France AM, Chen Y-H, et al. Progression and transmission of HIV (PATH
814		4.0)-A new agent-based evolving network simulation for modeling HIV transmission
815		clusters. Mathematical Biosciences and Engineering. 2021;18:2150–2181.
816	[60]	Liljeros F, Edling CR, Amaral LAN, et al. The web of human sexual contacts.
817		Nature. 2001;411:907–908.
818	[61]	Cohen SM, Gray KM, Ocfemia MCB, et al. The status of the National HIV
819		Surveillance System, United States, 2013. Public Health Rep. 129:335–341.
820	[62]	Grey JA, Bernstein KT, Sullivan PS, et al. Estimating the Population Sizes of Men
821		Who Have Sex With Men in US States and Counties Using Data From the American
822		Community Survey. JMIR Public Health Surveill. 2:e14.
823	[63]	Reece M, Herbenick D, Schick V, et al. Background and Considerations on the
824		National Survey of Sexual Health and Behavior (NSSHB) from the Investigators. J
825		Sex Med. 2010;7:243–245.
826	[64]	Chandra A, Mosher WD, Copen C, et al. Sexual behavior, sexual attraction, and
827		sexual identity in the united states: Data from the 2006-2008 national survey of
828		family growth. Sexual Statistics: Select Reports from the National Center for Health
829		Statistics. 2013;19:1–74.
830	[65]	Buchacz K, Armon C, Palella FJ, et al. CD4 Cell Counts at HIV Diagnosis among
831		HIV Outpatient Study Participants, 2000–2009. AIDS Res Treat. 2012;2012:1–7.

832 833	[66]	Centers for Disease Control and Prevention. Behavioral and Clinical Characteristics of Persons Living with Diagnosed HIV Infection Medical Monitoring Project
833		United States 2016 Cycle (June 2016, May 2017) HIV Surveillance Special Report
835		[Internet] 2016 [cited 2022 Dec 20]:21 Available from:
836		http://www.cdc.gov/biv/library/reports/biv_surveillance.html
830	[67]	Derroch TM Winkler P. Anal concer and certical concer acrossing: Key differences
037	[07]	Concer Cytomethol 2011:110:5 10
030 920	[20]	Cancer Cytopathol. 2011;119:5–19.
839	[00]	CDC 2010
840	[60]	CDC. 2019.
841	[09]	Goparappa C, Guo J, Meckoni P, et al. A Two-Step Markov Processes Approach for Decomptonization of Concern State Transition Models for Low, and Middle Income
842 842		Parameterization of Cancer State-Transition Models for Low- and Middle-Income
843	[70]	Countries. Medical Decision Making. 2018;58:520–550.
844	[/0]	Jonnson HC, Elistrom KM, Edmunds WJ. Inference of Type-Specific HPV
845		I ransmissibility, Progression and Clearance Rates: A Mathematical Modelling
846	[7]1]	Approach. PLoS One. 2012; /:e49614.
847	[/1]	Joste NE, Ronnett BM, Hunt WC, et al. Human Papillomavirus Genotype-Specific
848		Prevalence across the Continuum of Cervical Neoplasia and Cancer. Cancer
849	[70]	Epidemiology, Biomarkers & Prevention. 2015;24:230–240.
850	[/2]	Burger EA, de Kok IMCM, Groene E, et al. Estimating the Natural History of
851		Cervical Carcinogenesis Using Simulation Models: A CISNET Comparative
852	[70]	Analysis. JNCI: Journal of the National Cancer Institute. 2020;112:955–963.
853	[/3]	Laskey PW, Meigs JW, Flannery JT. Uterine Cervical Carcinoma in Connecticut,
854		1935–1973: Evidence for Two Classes of Invasive Disease2. JNCI: Journal of the
855	57 43	National Cancer Institute. 19/6;5/:103/–1043.
856	[/4]	Kim JJ, Campos NG, Sy S, et al. Inefficiencies and High-Value Improvements in
857	[ <b>7</b> ]	U.S. Cervical Cancer Screening Practice. Ann Intern Med. 2015;163:589–597.
858	[/5]	Burger EA, Smith MA, Killen J, et al. Projected time to elimination of cervical
859		cancer in the USA: a comparative modelling study. Lancet Public Health.
860	<b>17</b> (1)	2020;5:e213-e222.
861	[76]	National Cancer Institute. Surveillance, Epidemiology, End Results (SEER) Cancer
862		Statistics Review, 1975-2013. [Internet]. [cited 2022 Dec 20]. Available from:
863		https://seer.cancer.gov/archive/csr/19/5_2013/.
864	[//]	Schuman P, Ohmit SE, Klein RS, et al. Longitudinal Study of Cervical Squamous
865		Intraepithelial Lesions in Human Immunodeficiency Virus (HIV)–Seropositive and
866	[70]	At-Risk HIV-Seronegative Women. J Infect Dis. 2003;188:128–136.
867	[/8]	Liu G, Sharma M, Tan N, et al. HIV-positive women have higher risk of human
868		papilloma virus infection, precancerous lesions, and cervical cancer. AIDS.
869	5701	2018;32:795–808.
870	[/9]	Walker TY, Elam-Evans LD, Singleton JA, et al. National, Regional, State, and
871		Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years
872	1001	— United States, 2016. MMWR Morb Mortal Wkly Rep. 201/;66:8/4–882.
873	[80]	Reagan-Steiner S, Yankey D, Jeyarajah J, et al. National, Regional, State, and
874		Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years
875		— United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64:784–792.

876	[81]	Centers for Disease Control and Prevention. Use of Selected Clinical Preventive
877		Services to Improve the Health of Infants, Children, and Adolescents — United
878		States, 1999–2011. MMWR . 2014;63.
879	[82]	Centers for Disease Control and Prevention. HIV Surveillance Report, 2020. 2020
880		[cited 2022 Dec 20];33. Available from: http://www.cdc.gov/hiv/library/reports/hiv-
881		surveillance.html.
882	[83]	Frieden TR. A framework for public health action: the health impact pyramid. Am J
883		Public Health. 2010;100:590–595.
884	[84]	Oster AM, France AM, Panneer N, et al. Identifying Clusters of Recent and Rapid
885		HIV Transmission Through Analysis of Molecular Surveillance Data. J Acquir
886		Immune Defic Syndr. 2018;79:543–550.
887	[85]	Marra E, Lin C, Clifford GM. Type-Specific Anal Human Papillomavirus Prevalence
888		Among Men, According to Sexual Preference and HIV Status: A Systematic
889		Literature Review and Meta-Analysis. J Infect Dis. 2019;219:590–598.
890	[86]	Liu X, Lin H, Chen X, et al. Prevalence and genotypes of anal human papillomavirus
891		infection among HIV-positive vs . HIV-negative men in Taizhou, China. Epidemiol
892		Infect. 2019;147:e117.
893	[87]	Burger EA, Dyer MA, Sy S, et al. Development and Calibration of a Mathematical
894		Model of Anal Carcinogenesis for High-Risk HIV-Infected Men. J Acquir Immune
895		Defic Syndr. 2018;79:10–19.
896	[88]	McCree DH, Oster AM, Jeffries WL, et al. HIV acquisition and transmission among
897		men who have sex with men and women: What we know and how to prevent it. Prev
898		Med (Baltim). 2017;100:132–134.
899	[89]	Raymond HF, Al-Tayyib A, Neaigus A, et al. HIV Among MSM and Heterosexual
900		Women in the United States: An Ecologic Analysis. JAIDS Journal of Acquired
901		Immune Deficiency Syndromes. 2017;75:S276–S280.
902		